JARID2 Inhibition Reprograms Human Hematopoietic Progenitor Cells To Enhance Bone Marrow Transplantation

Blood Advances · Available online 23 Jul 2026 · In press · DOI 10.1182/bloodadvances.2025019220

Free full text

Authors (16)

Wentao Han, Hassan Bjeije, Hamza Celik, Michael Rettig, Nancy Issa, Andrew L. Young, Yanan Li, Infencia Xavier Raj, Christine R. Zhang, Aishwarya Krishnan, Tyler M. Parsons, Samantha C. Burkart, Jason Arand, Wei Yang, Jeffrey A. Magee, Grant A. Challen

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Han, W., Bjeije, H., Celik, H., et al. (2026). JARID2 Inhibition Reprograms Human Hematopoietic Progenitor Cells To Enhance Bone Marrow Transplantation. Blood Advances. https://doi.org/10.1182/bloodadvances.2025019220

Related articles

• Long-term experience with emicizumab in people with hemophilia A in the Canadian Bleeding Disorders Registry · Blood Advances · 2026 · Same journal
• Chronic GVHD Consortium CATCH Study: Incidence, initial presentation and risk factors for chronic GVHD development · Blood Advances · 2026 · Same journal
• Incidence and clinical impact of absolute lymphocyte count-only progression in chronic lymphocytic leukemia · Blood Advances · 2026 · Same journal
• Comprehensive analysis of prognostic factors in myelodysplastic syndromes with isolated deletion of chromosome 5q · Blood Advances · 2026 · Same journal
• Reframing Hematologic and Thrombovascular Care for Transgender and Gender-Diverse Individuals: A Scoping Review · Blood Advances · 2026 · Same journal
• Frequency, kinetics, and clinical significance of HHV-6 DNAemia after PTCy-based hematopoietic cell transplant · Blood Advances · 2026 · Same journal
• Optimizing outcomes and accessibility of matched sibling donor transplant for transfusion dependent thalassemia in LMICs · Blood Advances · 2026 · Same journal
• The zebrafish model tackles anti-P2Y12 variability in humans: a translational approach · Blood Advances · 2026 · Same journal
• A Phase 1/1b Study of the All-Oral Regimen CC-486 and Venetoclax in Acute Myeloid Leukemia · Blood Advances · 2026 · Same journal
• In vivo and ex vivo impact of THBD and PROCR polymorphisms on the anticoagulant response of the protein C pathway · Blood Advances · 2026 · Same journal